GlassScriptPhysician profile
Mustafa Ammar
NPI 1558363168
$3,675.61
in general payments reported to CMS, 2019-2025
28 companies · $796 in 2025
The $796 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $194 · 2021: $33.92 · 2022: $398 · 2023: $849 · 2024: $836 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.18 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $549.93 | 2019-2025 | Apretude, Dovato, Rukobia |
| Abbvie INC. | $520.11 | 2019-2025 | Linzess, Ubrelvy, Viberzi |
| Merck Sharp & Dohme LLC | $451.81 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Janssen Pharmaceuticals, INC | $356.15 | 2019-2023 | Xarelto, Spravato |
| Gilead Sciences, INC. | $352.75 | 2019-2025 | Yeztugo |
| Astrazeneca Pharmaceuticals LP | $216.21 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $173.05 | 2019-2025 | Bexsero, Penmenvy, Arexvy |
| Pfizer INC. | $170.03 | 2019-2025 | |
| Novo Nordisk INC | $167.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $116.98 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $66.68 | 2022 | |
| Janssen Biotech, INC. | $57.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.69 | 2023-2025 | |
| Daiichi Sankyo INC. | $49.51 | 2025 | Injectafer |
| Genzyme Corporation | $47.52 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.14 | 2024-2025 | Repatha, Otezla, Otezla |
| Alk-Abello, INC | $34.23 | 2023 | Grastek, Odactra |
| Medtronic, INC. | $32.74 | 2023 | Venaseal |
| Sunovion Pharmaceuticals INC. | $28.70 | 2019 | |
| Madrigal Pharmaceuticals | $28.65 | 2025 | Rezdiffra |
| Lilly USA, LLC | $27.47 | 2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $25.07 | 2024 | Dupixent |
| Alkermes, INC. | $24.62 | 2023 | Vivitrol |
| Qiagen, LLC | $20.39 | 2024 | |
| Novavax INC | $19.48 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Theratechnologies INC. | $16.42 | 2025 | Trogarzo, Egrifta |
| Cranial Technologies, INC | $14.34 | 2024 | Doc Band |
| Advanced Respiratory, INC | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mustafa Ammar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.